Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy

Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles-solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid-polymer hybrid nanoparticles-have received particular interest in antica...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-01, Vol.15 (1), p.216
Main Authors: Marques, Ana Camila, Costa, Paulo C, Velho, Sérgia, Amaral, Maria Helena
Format: Article
Language:English
Subjects:
active targeting
Adsorption
Antibodies
Antigens
cancer
Cancer therapies
Drug delivery systems
functionalization
Immunoglobulins
Ligands
lipid nanoparticles
Lipids
Nanoparticles
Polyethylene glycol
Review
SLN
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanotechnology takes the lead in providing new therapeutic options for cancer patients. In the last decades, lipid-based nanoparticles-solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), liposomes, and lipid-polymer hybrid nanoparticles-have received particular interest in anticancer drug delivery to solid tumors. To improve selectivity for target cells and, thus, therapeutic efficacy, lipid nanoparticles have been functionalized with antibodies that bind to receptors overexpressed in angiogenic endothelial cells or cancer cells. Most papers dealing with the preclinical results of antibody-conjugated nanoparticles claim low systemic toxicity and effective tumor inhibition, which have not been successfully translated into clinical use yet. This review aims to summarize the current "state-of-the-art" in anticancer drug delivery using antibody-functionalized lipid-based nanoparticles. It includes an update on promising candidates that entered clinical trials and some explanations for low translation success.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15010216